Klebsiella pneumoniae is a rod shaped type of bacteria commonly found in the normal flora of the mouth, skin, and intestines.
K. pneumoniae can in turn cause an infection called klebsiella pneumonia. This can provoke lung inflammation and cell death that may produce a thick, bloody, mucoid sputum. This often happens after the bacteria migrate from their normal place of resting to the lower respiratory tract. (For more on this see the questions below)
The KPC superbug arises when the Klebsiella bacteria become resistant to the carbapenem drugs often used to treat them. These drug resistant bacteria are called Carbapenemases. They are active in other bacteria beside Klebsiella and this resistance group are sometimes referred to as Carbapenem Resistant En (CRE)
Different types of KPC exist around the world and are most often seen in hospital patients with compromised immune systems and significant exposure to hospital infections. They have spread around the USA in the last 10 years and often have a foothold in long term care facilities.
They have gained media attention since September 2012 because of the interest in the battle that the National Insitute of Health experienced in uprooting the infection from their state of the art facility and the many deaths that have occurred from one single outbreak. KPC and CRE are considered to be among the most potent threats to public health in the world at this time. They threaten to turn formerly treatable infections into life ending challenges.
See our KPC superbug guide below
- KPC News – Daily Updates
- How is the KPC superbug treated
- What are KPC superbug symptoms
- What is Klebsiella Pneumonia?
- What is the KPC superbug?
The latest news on carbapenemases is below. You can sign up for our weekday newsletter here
- antimicrobial resistance: CSE welcomes National Action Plan to curb Antimicrobial Resistance; lauds move to set up authority - The Times of India on Mobile
- Study details optimal combo therapy for drug-resistant bacteremia | CIDRAP
- Novel phage therapy saves patient with multidrug-resistant bacterial infection | Scienmag: Latest Science and Health News
- California advances bill to track deadly superbug infections | abc7.com
- Promiscuous plasmids: a rapid reflection from ECCMID 2017 | Reflections on Infection Prevention and Control
- Can we halve Gram-negative BSIs by 50% by 2021? The crowd say “No” | Reflections on Infection Prevention and Control
- Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis - The Lancet Infectious Diseases
- Faropenem Consumption is Increasing in India. - PubMed - NCBI
- Predictors of Heavy Stethoscope Contamination Following a Physical Examination | Infection Control & Hospital Epidemiology | Cambridge Core
- Duration of Colonization With Klebsiella pneumoniae Carbapenemase-Producing Bacteria at Long-Term Acute Care Hospitals in Chicago, Illinois | Open Forum Infectious Diseases | Oxford Academic
- WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
- ESBL- and Carbapenemase-Producing Enterobacteriaceae in Patients with Bacteremia, Yangon, Myanmar, 2014.
- Presence of multidrug-resistant organisms in the residents and environments of long-term care facilities in Taiwan. - PubMed - NCBI
- EUropean prospective cohort study on Enterobacteriaceae showing REsistance to CArbapenems (EURECA): a protocol of a European multicentre observationa... - PubMed - NCBI
- A Pseudomonas aeruginosa Quorum-Sensing autoinducer analog enhances the activity of antibiotics against resistant strains. - PubMed - NCBI